The device operates around the company’s new Theranova dialyzer designed to extend the range of molecules that it filters from the blood, claiming it “more closely mimics the natural kidney.”
”Through HDx enabled by Theranova, Baxter is introducing a major advancement in hemodialysis, an area that has seen little improvement in recent years. We expect HDx enabled by Theranova to advance hemodialysis care for millions of patients around the world.,” renal biz prez Giuseppe Accogli said in a press release.
The company touted a recent study published in Nephrology Dialysis Transplantation which reported that the Theranova dialyzer removed a wide range of middle molecules more effectively than high-flux dialyzer FX CorDiax.
The study also reported the device exceeded the performance of high-volume HDF for large solutes, with moderate albumin removal.
Baxter said it has perviously won clearance in the regions it plans to launch in, but is not yet cleared in the United States.
Satellite, a non-profit group, is the 6th-largest dialysis and kidney disease treatment provider in the U.S. The 4-year deal will see Satellite deploy Baxter’s Amia automated peritoneal dialysis system and Revaclear dialyzer for high-flux hemodialysis. Baxter won 510(k) clearance from the FDA in October 2015 for the Amia system.
The financial details of the agreement were not disclosed.